Odyssey Therapeutics, Inc. (ODTX)
Nasdaq: ODTX · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal quarter | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|
| Period ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 |
| Report filed | Nov 4, 2026 | Aug 6, 2026 | Jun 17, 2026 |
| Revenue | 0 | 0 | 0 |
| Research and development | 42,121 | 36,226 | 32,321 |
| General and administrative | 11,240 | 10,511 | 7,350 |
| Total operating expenses | 56,668 | 55,470 | 39,780 |
| Operating income | -56,668 | -55,470 | -39,780 |
| Interest expense | 12 | 20 | 10 |
| Interest and investment income | 3,864 | 2,832 | 1,708 |
| Other income (expense), net | -194 | -138 | -117 |
| Total non-operating income (expense) | 3,658 | 2,674 | 1,581 |
| Income before income taxes | -53,010 | -52,796 | -38,199 |
| Income tax expense | 49 | -8 | 63 |
| Net income including non-controlling interests | · | · | -38,262 |
| Net income | -53,059 | -52,788 | -38,262 |
| Net income to common shareholders | -53,059 | -52,788 | -38,262 |
| Earnings per share, basic | -1.10 | -1.74 | -6.77 |
| Earnings per share, diluted | -1.10 | -1.74 | -6.77 |
| Weighted average shares, basic | 48,018,265 | 30,277,051 | 5,655,716 |
| Weighted average shares, diluted | 48,018,265 | 30,277,051 | 5,655,716 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Each quarter is three months. A fourth quarter prints only where the company tagged its three months on their own; the whole year is in the annual view.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding